Summit Therapeutics stock drops about 5.5% after FDA issues Complete Response Letter on ivonescimab

Summit Therapeutics stock drops about 5.5% after FDA issues Complete Response Letter on ivonescimab
Summit therapeutics slides 5.49% today

Summit Therapeutics (SMMT) fell 5.49% after investors reacted to the recent regulatory setback in its lung cancer drug application. The move is supported by strong seller pressure, with the stock trading below all major moving averages.

SMMT price prediction
24H 3.02%
$10.23
48H 1.31%
$10.06
7D -2.01%
$9.73
1M 3.22%
$10.25
3M -0.81%
$9.85
6M 7.15%
$10.64
12M -5.24%
$9.41
Current price: $9.93 -0.6437 6.09%
Closed 11/20
Daily range 10.19 Arrow from to Icon 10.61
Weekly range 10.15 Arrow from to Icon 13.27
Loading...

Highlights

  • Summit Therapeutics received a Complete Response Letter from the FDA declining approval of ivonescimab for lung cancer in its first US application.
  • The company will start a global Phase III trial named HARMONi-10 studying ivonescimab in non-small cell lung cancer.
  • Shares of Summit Therapeutics closed at $9.99, down 5.49%, with strong seller pressure and a five-day forecast range of $8.43 to $11.55.

Regulatory rejection and new trial plans shift investor sentiment

Summit Therapeutics recently received a Complete Response Letter from the FDA, which declined to approve its investigational lung cancer drug, ivonescimab, for its initial US application. Following this development, Summit announced the launch of a new global Phase III clinical trial for ivonescimab targeting non-small cell lung cancer under the HARMONi-10 trial. The company also scheduled a corporate update and operational progress conference call and webcast for November 30, 2026.

Anton Kharitonov, expert at Traders Union, views Summit Therapeutics as under significant pressure after its lung cancer drug setback. He points to all key indicators signaling strong bearish control, with the price far below critical moving averages and no relief from selling momentum. The failed FDA approval and company’s urgent need to relaunch clinical trials show elevated regulatory risk. Kharitonov believes investor confidence remains low, and the oversold technicals alone are not enough for a durable rebound. He notes, "Traders should stay defensive as the downside risk remains the dominant scenario until a clear reversal emerges."
Viktoras Karapetjanc, expert at Traders Union, sees opportunity despite the recent decline in SMMT. He highlights management's quick move to start a new Phase III trial as a sign of commitment and adaptability. Karapetjanc views the HARMONi-10 initiative as setting the stage for a potential turnaround and renewed investor interest. He believes the market often rewards swift, transparent responses to regulatory feedback. "I expect that with the new clinical trial underway, SMMT can attract fresh optimism and the bullish structure could rebuild rapidly," says Karapetjanc.
Jainam Mehta, market strategist, notes SMMT is at a tactical inflection point as oversold readings coincide with further downside risk. He believes the sharp drop has shaken out many weak hands, potentially priming the stock for a short-term volatility spike. Mehta suggests monitoring for a contrarian rebound above $11.55 if momentum shifts, while risk remains pronounced below $8.43. He states, "A tactical long setup may emerge on a confirmed momentum reversal, but until then, caution is warranted."
Summit Therapeutics asset chart
Summit Therapeutics price dynamics. Source: TradingView.

Bearish momentum persists as key supports erode amid volatility

SMMT is trading below the 20-, 50-, and 200-day moving averages ($14.79, $15.89, and $16.08), showing clear seller pressure and a bearish structure across all timeframes. The nearest resistance stands at $10.15, with short-term support at $8.43. Momentum signals remain negative, with both the MACD and ADX reflecting a continued sell bias. The Relative Strength Index (RSI) holds neutral, while the Stochastic RSI and CCI are in their oversold zones, suggesting a possible rebound but with sellers still dominating. The Awesome Oscillator further signals downside momentum. Trading activity has remained pressured, with the price nearly at the session low and intraday volatility at 4.12%.

Earlier, analysts noted that Summit Therapeutics remained technically pressured following regulatory delays related to its lung cancer drug ivonescimab. This outlook is reinforced in the current environment, where continued downside momentum places $8.43 as a critical support level to monitor for potential breakdown or consolidation.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.